I just can’t write about stocks today. I want to, but I can’t. My mind is on baseball. You see, I manage my 8-year-old son’s Little League team. And they had their first playoff game last Thursday.

Last week I tried to open a savings account for my son. The credit union offered me a 1% interest rate… If I had given my money to the credit union, I would have guaranteed my son a 5% annual loss.

There’s a lot of talk lately about oil and gas. Naturally, I’ got an e-mail from Wayne M. asking…

This company is a value investor’s dream. Not only can you double your money with this stock… but you can also collect a 12.7% dividend payout while you wait!

You could almost hear the champagne corks popping. After declining for five consecutive months, the S&P 500 clawed its way to a 4.7% gain in April. Yeah! Yippee! Hoo-rah!

Right now, we have a rare opportunity. We can get paid a monthly double-digit dividend… We can buy in for only 85 cents on the dollar… And we can have the skills of a legendary investment manager behind us.

Great businesses at bargain prices…Especially in manufacturing…Take a look at this quality going cheap…Back from holiday I trawl through ten days of company announcements, to find that one of my supposedly long-term relationships may soon become no more than a quick affair.

In the words of my father-in-law, “The stock market stinks.” Benny was lamenting over the performance of his S&P 500 index mutual fund. He bought the fund back in 1999. And he sold it just a few weeks ago.

Back in December, I told you the bleak story of Neurocrine Biosciences (NBIX). A week earlier, the company had received a crushing blow from the FDA, dished out in a notorious “approvable letter.” Approvable letters are the FDA’s way of turning a “yes/no” decision on a new drug into a “maybe.”